ALSO NOTED: Pfizer's Kindler can't quash mega-deal talk; FDA to review Pegintron;and much more...

> Some Pfizer investors are clamoring again for a big acquisition just days after CEO Jeff Kindler said he wouldn't play Let's Make a Deal. Mega-M&A is just too disruptive, Kindler said at last Wednesday's analyst confab. But a CreditSuisse analyst maintains that "a large scale deal may be the best option" for shoring up the company. Report

> The FDA has delayed an advisory board meeting to review the use of Pegintron for serious skin cancer. Report

> The FDA has approved Spectrum Pharmaceuticals' Levoleucovorin for injection after high-dose methotrexate therapy in patients with osteosarcoma. A supplemental NDA for colorectal cancer is planned for mid-year. Release

> The FDA has approved Auriga Laboratories' Liquadd Oral Solution 5 mg/5 mL for ADHD. Release

> Is it a pre-emptive strike? Late Friday Amgen added new warnings to the embattled anemia drugs Aranesp (Amgen) and Procrit (Johnson & Johnson). Report

> Is Pfizer eyeing Chinese outsourcing? Report

> What does it take to cut a CEO's compensation package by almost 20 percent? Ask David Brennan (photo), head honcho at AstraZeneca. Report

And Finally... Don't drink the water? Prescription drugs are in the water supply of more than two dozen cities, according to an investigation that's sure to catch a lot of attention over the next few days. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.